Wounds and Injuries
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.
Subtype terms (53)
More specific conditions that are subtypes of Wounds and Injuries in the MeSH hierarchy.
- Abdominal Injuries
40 drugs (27 approved, 13 experimental)
- Accidental Injuries
1 drug approved
- Amputation, Traumatic
6 drugs approved
- Arm Injuries
13 drugs (11 approved, 2 experimental)
- Asphyxia
13 drugs (10 approved, 3 experimental)
- Athletic Injuries
11 drugs (7 approved, 4 experimental)
- Back Injuries
10 drugs (7 approved, 3 experimental)
- Barotrauma
2 drugs approved
- Birth Injuries
2 drugs (1 approved, 1 experimental)
- Bites and Stings
16 drugs (14 approved, 2 experimental)
- Burns
220 drugs (131 approved, 89 experimental)
- Cold Injury
7 drugs (3 approved, 4 experimental)
- Contrecoup Injury
- Crush Injuries
3 drugs (2 approved, 1 experimental)
- Drowning
1 drug experimental
- Electric Injuries
- Esophageal Perforation
- Extravasation of Diagnostic and Therapeutic Materials
4 drugs approved
- Foreign Bodies
- Fractures, Bone
135 drugs (99 approved, 36 experimental)
- Fractures, Cartilage
- Frostbite
3 drugs (2 approved, 1 experimental)
- Hand Injuries
42 drugs (37 approved, 5 experimental)
- Heat Stress Disorders
5 drugs approved
- Hip Injuries
24 drugs (21 approved, 3 experimental)
- Joint Dislocations
5 drugs approved
- Lacerations
15 drugs approved
- Leg Injuries
23 drugs (21 approved, 2 experimental)
- Microtrauma, Physical
- Multiple Trauma
27 drugs (24 approved, 3 experimental)
- Nasal Septal Perforation
11 drugs (8 approved, 3 experimental)
- Neck Injuries
- Occupational Injuries
- Radiation Injuries
11 drugs (10 approved, 1 experimental)
- Reinjuries
- Retropneumoperitoneum
- Rupture
4 drugs approved
- Self Mutilation
1 drug approved
- Shock, Traumatic
8 drugs (4 approved, 4 experimental)
- Shoulder Injuries
45 drugs (33 approved, 12 experimental)
- Soft Tissue Injuries
36 drugs (22 approved, 14 experimental)
- Spinal Cord Injuries
211 drugs (108 approved, 103 experimental)
- Sprains and Strains
100 drugs (59 approved, 41 experimental)
- Surgical Wound
31 drugs (17 approved, 14 experimental)
- Tendon Injuries
31 drugs (23 approved, 8 experimental)
- Thoracic Injuries
11 drugs (9 approved, 2 experimental)
- Tooth Injuries
1 drug experimental
- Trauma, Nervous System
7 drugs (6 approved, 1 experimental)
- Tympanic Membrane Perforation
12 drugs (5 approved, 7 experimental)
- Vascular System Injuries
10 drugs (5 approved, 5 experimental)
- War-Related Injuries
- Wounds, Nonpenetrating
3 drugs approved
- Wounds, Penetrating
2 drugs approved
Drugs by status
Approved for this indication (25)
- acetylcysteine
- debrisan
- centella asiatica
- epidermal growth factor
- manuka honey
- carbidopa
- platelet-rich plasma
- polydeoxyribonucleotide
- plasma rich in growth factors
- collagen
- calcium alginate
- autologous platelets
- autologous adipose tissue
- menthol
- triamcinolone
- methyl salicylate
- fibrinolysin, human
- pentafluoropropane
- ketanserin
- phenylmercury borate
- dehydrated human amnion-chorion membrane
- sodium alginate
- beremagene geperpavec
- umbilical cord blood platelet lysate
- channa striata extract
Phase 4 trials (56)
- ringer's lactate
- metronidazole
- aloe vera
- petrolatum, white
- ketamine
- clavulanate
- ibuprofen
- valproic acid
- gabapentin
- human placenta hydrolysate
- fibrinogen (human)
- lorazepam
- magnesium oxide
- amoxicillin
- methocarbamol
- vitamin c
- sodium picosulfate
- ropivacaine
- acetaminophen
- magnesium sulfate
- lidocaine
- propranolol
- levobupivacaine
- acetylsalicylic acid
- sufentanil
- bupivacaine
- estradiol
- testosterone
- pantoprazole
- tramadol
- +26 more
Phase 3 trials (39)
- propofol
- heparin
- leptospermum honey
- aliviador
- vitamin e
- human fibrin
- autologous plasma
- urea
- epoetin
- C1 Esterase Inhibitor (Human)
- energi-f703
- gelatin
- tacrolimus
- icosapent ethyl
- indocyanine green
- iodine
- loxoprofen
- mepivacaine
- octenidine
- oleogel-s10
- platelet rich fibrin
- honey
- red blood cells
- coagulation factor viia (recombinant)
- platelets
- alemtuzumab
- thiamine
- whole blood
- tr 987
- dexmedetomidine
- +9 more
Phase 2 trials (52)
- dalfampridine
- albendazole
- anlotinib
- plerixafor
- oxandrolone
- ar101
- castor oil
- oxycodone
- cstc1
- doxycycline
- hydroxypropyl-beta-cyclodextrin
- glyc-101
- lapatinib
- hemoglobin based oxygen carrier-201
- bone marrow derived mesenchymal stem cells
- rosuvastatin
- insulin human
- ketorolac
- iron dextran
- ivermectin
- lna043
- metoclopramide
- metolazone
- hemoglobin pegylated
- epinephrine
- remimazolam
- rhu-pgelsolin
- rph201
- sacchachitin
- oritavancin
- +22 more
Phase 1 trials (18)
Other trials (48)
- diclofenac
- melatonin
- vitamin d3
- methylprednisolone
- sucrose
- acellular dermal matrix
- paroxetine
- cefazolin
- citalopram
- coconut oil
- diphenhydramine
- duloxetine
- epiceram
- erythropoetin beta
- esp protein
- fluvoxamine
- sertraline
- hydrocolloid
- etomidate
- ozone
- leukocytes
- fluoxetine
- mupirocin
- human factor ix complex (prothrombin complex concentrate)
- potassium chloride
- prazosin
- caffeine
- hyaluronic acid
- alteplase
- trazodone
- +18 more
Organizations
Organization Involved with Phase 4 Indications (209)
- Mylan
- Kessler Institute for Rehabilitation
- Chonnam National University
- Shahid Beheshti University of Medical Sciences
- The Moody Foundation
- RUMCN
- University of Pennsylvania
- University of Missouri
- Medecins Sans Frontieres
- Baylor University
- University of Wisconsin
- City University of Hong Kong
- Jiao Tong University
- Medy-Tox
- University of North Carolina at Chapel Hill
- Inha University
- Simon Fraser University
- University of Colorado
- Chonbuk National University
- Brown University
- Canadian Forces Health Services Group
- Shire
- ZonMw: The Netherlands Organisation for Health Research and Development
- University of Arizona
- Universitat Internacional de Catalunya
- Pusan National University
- New York University
- Chung-Ang University
- University of Copenhagen
- University of Michigan
- +179 more
Organization Involved with Phase 3 Indications (161)
- Daewon Pharmaceutical Co., Ltd.
- Government of Mexico
- ICON
- Spanish Society for Emergency Medicine (SEMES)
- Royal Marsden Hospital NHS Trust
- Emory University
- National Health and Medical Research Council, Australia
- Assistance Publique - Hôpitaux de Paris
- Hebei University
- Acorda Therapeutics
- R3 Stem Cell
- Monash University
- Pennsylvania State University
- Vertex
- Cerimon Pharmaceuticals
- Ludwig Maximilians University
- Dijkzigt Hospital
- Premier Research Group
- ORION Clinical Services
- University of Maryland
- Dutch Burns Foundation
- Hillel Yaffe Medical Center
- University of California, Los Angeles
- University of Cologne
- Medical University Innsbruck
- Ningxia Medical University
- Tzu Chi University
- University of Trieste
- Columbia University
- Western Health
- +131 more
Organization Involved with Phase 2 Indications (215)
- StemCyte, Inc.
- Ocera Therapeutics
- Zhejiang University
- Stem Cells Arabia
- South East Sydney and Illawarra Area Health Service
- Wilkes University
- Hospital Sao Rafael
- University of Florida
- Merck Serono
- Atox Bio Ltd
- University of Baghdad
- CSL Behring
- Hallym University
- Hong Kong Academy of Medicine
- Unity Health Toronto
- Sanofi
- Wake Forest University
- Welsh Wound Innovation Centre Ltd
- National Cancer Institute (NCI)
- Ospedale Regionale di Lugano
- S-Evans Biosciences Co.,Ltd.
- Sclnow Biotechnology Co., Ltd.
- Basque Country University
- UCB
- Aiviva BioPharma Inc.
- Russian Academy of Medical Sciences
- Oakwood Southshore Hospital
- Mashhad University of Medical Sciences
- University of Padova
- Remedy Pharmaceuticals, Inc.
- +185 more
Organization Involved with Phase 1 Indications (49)
- Elysium Health
- Parexel
- Advent Health
- Pakistan Army
- Merck
- Pinteon Therapeutics, Inc
- Linkoping University
- Teva
- University of Bonn
- The University of Hong Kong
- The Institute for Rehabilitation and Research (TIRR) Foundation
- TCA Cellular Therapy
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Phagelux Inc.
- King Edward Medical University
- Children's Medical Center Dallas
- University of Texas, San Antonio
- Ocunexus
- Bukwang Pharmaceutical
- Semper Fi Fund
- University of Basel
- Gansu Provincial Maternity and Child-Care Hospital
- Tanox
- Exvastat Ltd.
- Orthopedic Research and Education Foundation
- University of Jordan
- Harch Hyperbaric Research Foundation
- University of Cambridge
- Bezmialem University
- Umea University
- +19 more
Organization Involved with Other Experimental Indications (68)
- University of Tennessee, Chattanooga
- Aultman Health Foundation
- Medical University of Gdansk
- Northern State Medical University
- City of Denver
- Yeshiva University
- Accumetrics, Inc.
- University of Athens
- Pooyesh Darou
- Providence Health & Services
- Mahidol University
- University of Groningen
- Instituto Nacional de la Nutrición Salvador Zubiran
- Henry Ford Health System
- Hormozgan University of Medical Sciences
- Dalian Medical University
- Ataturk University
- Institute of Liver and Biliary Sciences, India
- KCI
- Israel Cancer Association
- Advocate Healthcare
- Santa Barbara Cottage Hospital
- Allegiance Health
- HealthPartners Institute
- Fujian Medical University
- Pamukkale University
- University Hospital, Tours
- Hope Biosciences
- Advocate Health Care
- Laval University
- +38 more